Pliant Therapeutics
PLRX
110 hedge funds and large institutions have $925M invested in Pliant Therapeutics in 2022 Q3 according to their latest regulatory filings, with 44 funds opening new positions, 38 increasing their positions, 19 reducing their positions, and 21 closing their positions.
283% more capital invested
Capital invested by funds: $241M → $925M (+$684M)
167% more funds holding in top 10
Funds holding in top 10: 3 → 8 (+5)
146% more call options, than puts
Call options by funds: $4.22M | Put options by funds: $1.71M
110% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 21
100% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 19
25% more funds holding
Funds holding: 88 → 110 (+22)
9.92% more ownership
Funds ownership: 83.32% → 93.23% (+9.9%)
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$52.5M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$37.9M |
| 3 |
Jennison Associates
New York
|
+$33.3M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
+$27.5M |
| 5 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$26.8M |
Top Sellers
| 1 |
TGI
TRV GP III
Boston,
Massachusetts
|
-$38.3M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$18.5M |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$8.97M |
| 4 |
Goldman Sachs
New York
|
-$6.29M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$4.82M |
PLRX Hedge Fund Activity: Q3 2022 in Review
110 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Pliant Therapeutics (PLRX) for Q3 2022, worth a combined $925M — up 283% from $241M a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new PLRX positions and 21 closed out — a net gain of 23 holders — while 38 added to existing stakes and 19 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $52.5M. The largest seller was TRV GP III, cutting an estimated $38.3M.
- 110 institutional investors held Pliant Therapeutics (PLRX) as of Q3 2022, up from 88 in Q2 2022.
- Funds reported $925M of Pliant Therapeutics stock for Q3 2022, up 283% quarter-over-quarter.
- 44 funds opened new Pliant Therapeutics positions in Q3 2022 and 21 closed out, a net change of +23 holders.
- The largest Pliant Therapeutics buyer in Q3 2022 was Fidelity Investments, an estimated $52.5M added.
- The largest Pliant Therapeutics seller in Q3 2022 was TRV GP III, an estimated $38.3M sold.
Based on aggregated 13F filings for Q3 2022.